SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: j_fir2 who wrote (3613)8/17/1999 2:03:00 PM
From: John Metcalf  Read Replies (1) of 10280
 
Thanks, j fir2. I don't see how r-fluoxetine will conflict with the Fair Trade Act. To be in violation,

"(1) the act or practice causes or is likely to cause substantial injury to consumers; (2) which is not reasonably avoidable by consumers; and (3) is not outweighed by countervailing benefits to consumers or to competition."

Since the Lilly-Sepracor arrangement will not preclude availability of generic Prozac, after expiration of the Lilly patent, consumers can readily avoid using, or paying for, r-fluoxetine. In addition, the possibility of "countervailing benefits", like short washout period, is strong. Rkrw has made this point previously.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News